Rickettsial Panel (RMSF, Typhus), IgG

Laboratory Fee Schedule
Procedure #:  MCR0317A
CPT: 87040, 87070, 87077

Synonym(s): Rickettsia Rickettsii and Rickettsia Typhi IgG Antibody Detection by Indirect Immunofluorescence Assay (IFA)
Requisition Form G-2A
Test Description Standard IFA using a two-stage sandwich immunofluorescence technique for the detection of IgG antibodies to Rocky Mountain Spotted Fever and/or Typhus Fever antigens.
Pre-Approval Needed N/A
Supplemental Information Required N/A
Supplemental Form(s) N/A
Performed on Specimens from (sources) Human
Sample/Specimen Type for Testing Serum is preferred, plasma is accepted.
Minimum Volume/Size Required 1.0 mL
Storage/Preservation Prior to Shipping Specimens may be stored at 2°C to 8°C if testing will occur within 2 days; otherwise store frozen at -15°C or colder
Transport Medium N/A
Specimen Labeling At least 2 patient specific identifiers: First and last name as one identifier and a DOB or a unique patient specific identifier (e.g. Medical Record number); must match information on submission form (G-2A).
Shipping and Specimen Handling Requirements
  • Ship according to Dangerous Goods Regulations, IATA, and/or CFR 49.
  • Handle as infectious agent using universal precautions. 
  • Triple contained in accordance with federal shipping regulations for infectious agents. 

Additional forms & resources

Method Immunofluorescence Assay for the detection of antibodies
Turn-around Time 5 working days.
Interferences/Limitations Gross hemolysis, lipemia, bacterial contamination
Common Causes for Rejection Insufficient quantity, unacceptable specimen type or source, improper shipping conditions, expired media or collection container, discrepancies between specimen label and submission form, and/or incomplete or missing submission form.
Additional Information In order to confirm an infection was recent, a convalescent phase sample should be submitted.  The most convincing evidence of recent rickettsial disease is a fourfold rise in antibody titer between an acute phase serum and a convalescent phase serum.